Mr. Frazier is the founder and managing partner of Frazier Healthcare. Mr. Frazier assists with evaluating Growth Equity and Biopharma Venture investments. He has been integrally involved in growing several successful early-stage life science companies into national prominence, including Immunex, Affymax and Affymetrix. Mr. Frazier has led several successful investments for the firm such as Tularik and CV Therapeutic. Recently he has led the development of successful growth equity companies such as TridentUSA Health Services. Currently Mr. Frazier serves on the boards of Abode Healthcare, Cadence Pharmaceuticals (NASDAQ: CADX), Packaging Coordinators, and TridentUSA Health Services. Prior to forming Frazier Healthcare, Mr. Frazier was the Executive Vice President and Chief Financial Officer of Immunex Corporation. Later, he served as the Senior Financial Advisor and Chief Financial Officer of Affymax and worked on the spinout of Affymetrix. Prior to Immunex, Mr. Frazier was head of the Emerging Business Practice and co-head of the Technology Practice for the Seattle office of Arthur Young Company (now, Ernst & Young). Mr. Frazier holds a B.A. in Economics from the University of Washington.<\/p>\n